Prelude Capital Management, LLC Harrow Health, Inc. Call Options Transaction History

Prelude Capital Management, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$9.3 - $13.23 $115,320 - $164,052	12,400 New	12,400 $164,000
Q3 2023 Nov 14, 2023	BUY	$14.03 - $22.08 $210,450 - $331,200	15,000 New	15,000 $215,000
Q2 2020 Aug 14, 2020	SELL	$3.61 - $6.47 $612,617 - $1.1 Million	-169,700 Reduced 80.62%	40,800 $213,000
Q1 2020 May 15, 2020	BUY	$3.5 - $7.31 $281,050 - $586,993	80,300 Added 61.67%	210,500 $804,000
Q4 2019 Feb 14, 2020	SELL	$4.6 - $7.88 $531,300 - $910,140	-115,500 Reduced 47.01%	130,200 $1.01 Million
Q3 2019 Nov 14, 2019	BUY	$4.89 - $8.0 $1.2 Million - $1.97 Million	245,700 New	245,700 $1.38 Million

177

21.4M

845K

717K

Ticker HROW
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 27,070,000
Market Cap $923M
Description
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.